DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

8-MOP (Methoxsalen) - Published Studies


8-MOP Related Published Studies

Well-designed clinical trials related to 8-MOP (Methoxsalen)

Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. [2009.04]

Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. [2006.10]

Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. [2003.03]

Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen. [2002.03]

A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. [2000.03]

Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. [2000.01]

Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. [2000.01]

Effects of water temperature on photosensitization in bath-PUVA therapy with 8-methoxypsoralen. [1998.10]

8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. [1996.08]

Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. [1994.10]

Bathing suit delivery of 8-methoxypsoralen for psoriasis: a double-blind, placebo-controlled study. [1994.08]

Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. [1992.10]

Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects. [1992.02]

Plasma levels of 8-methoxypsoralen following oral or bath-water treatment. [1991.07]

Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization. [1988.05]

Well-designed clinical trials possibly related to 8-MOP (Methoxsalen)

5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. [2010.03]

Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. [2007.11]

PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study. [2005.04]

Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. [2004.12]

Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA. [2004.11]

Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. [2004.05]

[Clinical observation on treatment of vitiligo with xiaobai mixture] [2003.08]

PUVA and PUVB in vitiligo--are they equally effective? [2001.08]

Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. [2001.01]

Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. [2000.07]

Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. [2000.02]

Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy. [1999.04]

Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. [1998.05]

Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis. [1997.04]

Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. [1997.02]

Effects of PUVA therapy on kidney allografts: results of a randomized prospective double-blind study. [1994]

Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation. [1994]

Food-induced increase in bioavailability of 5-methoxypsoralen. [1994]

Response of psoriasis to psoralen-UVB photochemotherapy. [1993.03]

Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. [1992.11]

Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. [1992.03]

Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. [1991.10]

Modulation of human cutaneous mast cell responsiveness by a single, low-dose, PUVA treatment. [1991.09]

A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. [1991.06]

5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. [1988.02]

5-Methoxy psoralen, etretinate, and UVA for psoriasis. [1987.12]

Other research related to 8-MOP (Methoxsalen)

Comparison of topical 8-methoxypsoralen and narrowband ultraviolet B with narrowband ultraviolet B alone in treatment-resistant sites in plaque-type psoriasis: a placebo-controlled study. [2011.12]

Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8-methoxypsoralen application. [2011.02]

Comparison of topical 8-methoxypsoralen and narrowband ultraviolet B with narrowband ultraviolet B alone in treatment-resistant sites in plaque-type psoriasis: a placebo-controlled study. [2011]

Comparative efficacy of narrow-band ultraviolet B phototherapy alone and its combination with topical 8-methoxypsoralen in psoriasis. [2010.11]

PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest. [2010.10.15]

8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. [2010.06.15]

Photoallergic contact dermatitis to 8-methoxypsoralen in Ficus carica. [2010.06]

Modulation of expression of IL-8 gene in bronchial epithelial cells by 5-methoxypsoralen. [2009.11]

Topical 8-methoxypsoralen increases the efficacy of narrowband ultraviolet B in psoriasis. [2009.10]

Treatment of acrodermatitis continua with topical 8-methoxypsoralen plus local narrowband ultraviolet B phototherapy. [2009.09]

Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. [2008.01]

In vivo photochemical skin micronucleus test using a sunlight simulator: detection of 8-methoxypsoralen and benzo[a]pyrene in hairless mice. [2007.07.10]

The effect of psoralen plus ultraviolet A in vitro in HUT-78 enhances by 5-aminolevulinic acid. [2007.04]

8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. [2006.12]

Photo-chemically induced DNA effects in the comet assay with epidermal cells of SKH-1 mice after a single oral administration of different fluoroquinolones and 8-methoxypsoralen in combination with exposure to UVA. [2006.10.10]

UVA-activated 8-methoxypsoralen (PUVA) causes G2/M cell cycle arrest in Karpas 299 T-lymphoma cells. [2006.10.02]

Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. [2006.07]

Dose dependent inhibitory effects of dietary 8-methoxypsoralen on NNK-induced lung tumorigenesis in female A/J mice. [2006.03.28]

Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. [2006.03]

Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet A therapy for chronic palmoplantar psoriasis. [2006.02]

Differential sensitivity of T lymphocytes and hematopoietic precursor cells to photochemotherapy with 8-methoxypsoralen and ultraviolet A light. [2006.01]

Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. [2005.11]

Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. [2005.09]

Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses. [2005.04]

Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. [2005]

Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy). [2005]

Biological consequences of 8-methoxypsoralen-photoinduced lesions: sequence-specificity of mutations and preponderance of T to C and T to a mutations. [2004.12]

Corynebacterium jeikeium sepsis after 8-methoxypsolaren photopheresis for cutaneous T-cell lymphoma. [2004.09]

1,4,8-trimethylfuro[2,3-H]quinolin-2(1H)-one, a new furocoumarin bioisoster. [2004.05]

The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. [2003.12]

High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients. [2003.09]

An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. [2003.07]

An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen. [2003.07]

The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion. [2003.03]

Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration. [2002.11]

Methoxsalen stimulates electrogenic Cl- secretion in the mouse jejunum. [2002.07]

Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP). [2001.12]

Does the minimal phototoxic dose after 8-methoxypsoralen baths correlate with the individual's skin phototype? [2001.08]

The effect of methoxsalen dose on ultraviolet-A-induced erythema. [2001.05]

Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment. [2001.04]

Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. [2001.02]

Microemulsions for topical delivery of 8-methoxsalen. [2000.10.03]

Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. [2000.10]

[In vitro study of emulsions containing methoxsalen] [2000.04]

DNA damage induced by 4,6,8,9-tetramethyl-2H-furo[2,3-h]quinolin-2-one, a new furocoumarin analog: biological consequences. [2000.03]

DNA damage induced by 4,6,8,9-tetramethyl-2H-furo[2,3-h]quinolin-2-one, a new furocoumarin analog: photochemical mechanisms. [2000.03]

Assessment of minimal phototoxic dose following 8-methoxypsoralen bath: maximal reaction on average after 5 days. [2000.01]

Hand and foot PUVA soaks: an audit of the Massachusetts General Hospital's experience from 1994 to 1998. [1999.10]

Treatment of T lymphocytes with 8-methoxypsoralen plus ultraviolet A induces transient but biologically active Th1-skewing cytokine production. [1999.08]

Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. [1999.05]

Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis. [1999.04]

Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis. [1998.09]

Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy. [1998.06]

Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis. [1998]

Comparison of 8-MOP aqueous bath and 8-MOP ethanolic lotion (Meladinine) in local PUVA therapy. [1998]

Time course of 8-methoxypsoralen-induced skin photosensitization in PUVA-bath photochemotherapy. [1997.10]

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. [1997.04.10]

Bath PUVA--an investigation of the distribution of trioxsalen (TMP) and 8-methoxypsoralen (8-MOP) in bathwater. [1997.02]

Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen. [1997]

Therapy with orally administered methoxsalen and ultraviolet A radiation during childhood increases the risk of basal cell carcinoma. The PUVA Follow-up Study. [1996.12]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017